Salazosulfapyridine induced hypersensitivity syndrome associated with reactivation of humanherpes virus 6.
A 22-year-old woman with ulcerative colitis developed skin eruptions, liver dysfunction, and atypical lymphocytes in the peripheral blood two weeks after she started taking salazosulfapyridine (SASP). Skin eruptions and liver damage were severe. Drug-induced lymphocyte stimulation test (DLST) for SASP was positive. She was diagnosed as having SASP-induced hypersensitivity syndrome (HS). Corticosteroid therapy was needed to suppress these reactions. The transient elevation of HHV-6 IgG titer paralleled the symptoms, which indicated that these reactions were associated with the reactivation of HHV-6. We suggest that HHV-6 IgG titer is one of the modalities for the diagnosis and the prediction of the clinical course of HS.
Kunisaki
Yuya
Y
Department of Internal Medicine, Kyushu Kousei-Nenkin Hospital, Fukuoka.
Goto
Hiroshi
H
Kitagawa
Kikuo
K
Nagano
Masanori
M
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000032:analysis; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000188:drug therapy*; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000209:etiology*; D005077:Exanthema Subitum / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D005500:Follow-Up Studies; D015654:Herpesvirus 6, Human / Q000276:immunology*; D006801:Humans; D011239:Prednisolone / Q000627:therapeutic use; D018570:Risk Assessment; D012460:Sulfasalazine / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome; D014775:Virus Activation / Q000187:drug effects*; D017735:Virus Latency / Q000187:drug effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000914:Antibodies, Viral; D012460:Sulfasalazine; D011239:Prednisolone